EMA formalises advice that prompted Merck to pull dyslipidemia drugs in EU
This article was originally published in SRA
Executive Summary
The European Medicines Agency’s scientific committee, the CHMP, has concurred with a first-of-its-kind recommendation by the agency's Pharmacovigilance Risk Assessment Committee that called for the suspension of the drug marketing authorisations for the dyslipidemia drugs, Tredaptive, Pelzont and Trevaclyn (nicotinic acid/laropiprant)1.